Clinical-stage biopharmaceutical company

Transforming lives through best-in-class therapies.

Vivasor advances a diversified portfolio of antiviral, oncology, and non-opioid pain therapies—each supported by human clinical experience.

Explore our pipeline ↘Partner with us →
6clinical programs
4operating companies
3therapeutic areas
01 Our approach

A portfolio built on human data, not preclinical promises.

Our strategy combines late-stage opportunity with scientific breadth. Six products span distinct mechanisms and indications, creating multiple independent paths to meaningful patient impact.

AntiviralOncologyNon-opioid pain
01

Clinically grounded

Every program in the portfolio has human clinical experience.

02

Multiple catalysts

Independent development milestones across the next several quarters.

03

Purpose-built companies

Focused teams pair deep domain expertise with disciplined execution.

02 Pipeline

Six therapies.
One shared ambition.

A diversified clinical portfolio advancing across infectious disease, oncology, and pain.

01
Antiviral

Olgotrelvir

Oral SARS-CoV-2 Mpro inhibitor
Outside-US commercial launch planned H2 2026

Approved in China
02
Oncology / ADC

OQY-3258

TROP2 antibody-drug conjugate
Breast and head & neck cancers

Phase 3
03
Oncology / ADC

OQY-6129

CD-38 antibody-drug conjugate
Multiple myeloma and expansion indications

Phase 1
04
Oncology

Fujovee

Dual EGFR / BTK inhibitor
NSCLC and B-cell malignancies

Registration path
05
Oncology

AC-0939

Next-generation FLT3 inhibitor
Acute myeloid leukemia

Early clinical
06
Non-opioid pain

RTX

Intra-articular TRPV1 agonist
Knee osteoarthritis and cancer pain

Phase 2

Development stages reflect lead indications. Expansion indications may be at earlier stages.

03 Our companies

Focused organizations.
Integrated ambition.

Vivasor’s products are developed and commercialized through four wholly integrated operating companies.

APAntiviral

ACEA Pharmaceuticals

Olgotrelvir

OQOncology · ADCs

OQORY

OQY-3258 · OQY-6129

AOOncology · Small molecules

ACEA Oncology

Fujovee · AC-0939

FTNon-opioid pain

Fire Therapeutics

RTX

04 Leadership

Experienced leaders.
Built for the next chapter.

Our team brings deep experience across drug discovery, clinical development, regulatory affairs, manufacturing, and finance.

HJ

Henry Ji, Ph.D.

Chairman & CEO

XX

Xiao Xu, M.D.

Chief Medical Officer

SS

Shawn Sahebi, Ph.D.

Chief Operating Officer

SM

Steven Ma

Chief Financial Officer

MB

Mark Brunswick, Ph.D.

SVP, Regulatory Affairs

JS

Janie Shi

SVP, Finance

RZ

Ruoping Zhang

VP, Manufacturing

AC

Avery Coyle

VP, Program Management

At an inflection point

Ready to partner.
Ready to advance.

We welcome conversations with potential partners, collaborators, and investors.

Start a conversation ↗